The nonprofit biotech Cure Rare Disease (CRD) is headed to the clinic with a CRISPR therapeutic aimed at halting the progression of Duchenne muscular dystrophy in single-patient dosing.
If you are not happy with the results below please do another search
50 search results for:
Within the next eight years, more than 3.5 million people in the United States are expected to be diagnosed with inflammatory bowel disease. With those rising numbers in mind, Bristol Myers Squibb is doubling down on treating the condition with a nearly $2 billion partnership with GentiBio to develop Treg therapies for patients with IBD.
The FDA will still allow continued distribution of sitagliptin containing NTTP with an acceptable intake limit of 37 ng per day and up to 246.7 ng per day.
JYNNEOS is administered beneath the skin (subcutaneously) as two doses, four weeks (28 days) apart. For individuals 18 years of age and older determined to be at high risk of monkeypox infection, the EUA now allows for a fraction of the JYNNEOS dose to be administered between the layers of the skin (intradermally).
Research engineers from the Massachusetts Institute of Technology have found a way to prevent scar tissue from disabling implantable devices. If established as safe and effective in humans, this technology could prove transformative in treating many diseases, such as diabetes.
Britain is launching a polio vaccine booster campaign for children in London aged below 10, after confirming that the virus is spreading in the capital for the first time since the 1980s.
Federal regulation of data privacy and security has been on the back burner for the past two years, but key members of Congress have been working behind the scenes to frame bipartisan legislation and the FTC is gearing up. The Supreme Court’s decision overturning Roe v. Wade may put this issue front and center in Congress after the midterms.
Supplies of a vaccine to prevent the deadly rotavirus infection in children have either run out in Kenya, Tanzania, Senegal and Cameroon or are close to doing so, officials close to the roll-out told Reuters, after disruptions at drugmaker GSK.
Health officials in Europe are discussing whether to follow a move by the United States to stretch out scarce monkeypox vaccine supplies, with the World Health Organization calling for more data.
Can decentralized and agile approaches also be applied to LTFUs and the collection of real-world evidence (RWE)? What does that look like, who’s interested in pursuing it, and what are the perceived benefits and pitfalls?